Clinical Trials Browser

loncastuximab tesirine × Clear all

NCT04970901 2026-03-13

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Phase 1 Recruiting

Lymphoma, B-Cell

NCT05658562 2026-02-13

A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

Phase 1/2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05053659 2026-02-12

Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

Phase 1 Active not recruiting

Lymphoma, Non-Hodgkin

NCT04998669 2026-02-10

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

Phase 2 Recruiting

Lymphoma, Follicular

NCT04384484 2026-01-26

LOTIS 5

Phase 3 Active not recruiting

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05464719 2026-01-12

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

Phase 2 Recruiting

Lymphoma

NCT05249959 2026-01-05

FIL_COLUMN

Phase 2 Recruiting

Lymphoma, Mantle-Cell

NCT05453396 2025-10-16

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

Phase 2 Recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05270057 2025-10-09

LONCA

Phase 1 Active not recruiting

Burkitt Lymphoma, Lymphoma, B-Cell

NCT05672251 2025-10-06

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05296070 2025-09-30

Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

Phase 2 Recruiting

Lymphoma, B-Cell, Marginal Zone

NCT07197307 2025-09-29

CLEAR

Phase 2 Not yet recruiting

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT06977711 2025-08-05

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

Phase 1 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05660395 2025-07-16

A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

Phase 1 Recruiting

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05190705 2025-05-23

Loncastuximab Tesirine in WM

Phase 2 Recruiting

Waldenstrom Macroglobulinemia

NCT06918912 2025-04-09

LORELY

Phase 2 Recruiting

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05144009 2025-01-30

LOTIS-9

Phase 2 Terminated

41 enrolled 19 charts

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03684694 2024-02-06

Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

Phase 1/2 Terminated

136 enrolled 33 charts

Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04699461 2023-10-23

LOTIS-6

Phase 2 Terminated

6 enrolled 9 charts

Lymphoma, Lymphoma, Follicular

NCT05228249 2023-01-13

Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Withdrawn

Lymphoma, Large B-Cell, Diffuse

NCT04974996 2022-03-29

LOTIS-8

Phase 1 Withdrawn

Lymphoma, Large B-Cell, Diffuse

NCT03685344 2021-10-26

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Phase 1 Terminated

13 enrolled 15 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02669264 2021-05-24

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Phase 1 Terminated

35 enrolled 31 charts

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02669017 2021-05-19

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

Phase 1 Completed

183 enrolled 38 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04705454 2021-05-12

Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

No longer available

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse